KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated AnalysisMarc Peeters, Scott D. Patterson, Yevhen Hotko et al.|Annals of Oncology|2014Cited by 3